Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPMA Health Policy Seminar
March 27, 2006
- Korosho Calls For Stable, Nationwide Supply of Generics at All Strengths
March 27, 2006
- Seminar
March 27, 2006
- Notification on Measures to Promote the Use of Generics Issued
March 27, 2006
- Seminar
March 27, 2006
- Towa, Sawai, and Nichi-iko Will Cooperate to Supply All Specifications
March 27, 2006
- New 3-year Regulatory Reform Plan Coming Soon
March 27, 2006
- Taiyo to Independently Supply All Specifications
March 27, 2006
- REGULATORY NEWS IN BRIEF
March 27, 2006
- JGPMA to Distribute "GE Drug Consultation Card" Free of Charge
March 27, 2006
- Notifications Issued to Explain New Medical Fees
March 27, 2006
- GSK to Begin Clinical Trial of Cervarix in Japan
March 27, 2006
- Rivalry Heats Up as Election Approaches: JMA
March 27, 2006
- Korosho Submits Proposal for "vaccine Industry Vision"
March 27, 2006
- Mr Kodama to Concentrate on JPA
March 27, 2006
- Aricept Improves Cognitive Function in Vascular Dementia: Eisai
March 27, 2006
- 200 Jobs Expected to Be Cut at Banyu by End of March
March 27, 2006
- Blopress Reduces Onset of Hypertension by 15.6%: Takeda
March 27, 2006
- SSP Extends Childcare-leave Period to 3 Years
March 27, 2006
- Crestor Reverses Plaque Build-up in Coronary Artery Disease
March 27, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…